ӳ����ý

Collaboration between ӳ����ý and Bayer leads to new treatment for a hard-to-treat type of lung cancer.

Researchers have developed a genome-editing strategy that targets a common cause of roughly 30 percent of rare diseases and could vastly improve access to gene-editing treatments for patients.

Stimulating the liver to produce some of the signals of the thymus can reverse age-related declines in T-cell populations and enhance response to vaccination.

Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder that begins in infancy.

The ӳ����ý core member and gene editing pioneer describes a framework that could enable the treatment of 1,000 patients with personalized gene editing therapies by 2030.

PopEVE can identify genetic variants most likely to cause severe disease, death.

By classifying acute leukemia samples based on methylation patterns, MARLIN reduces diagnosis time from days to hours.

ӳ����ý scientists describe how data resources they helped build over more than a decade now form the foundation for cutting-edge AI and genome biology discoveries.

Trained with a joint understanding of protein and cell behavior, the model could help with diagnosing disease and developing new drugs.

AI-based approaches yield novel antibiotics that show promise against gonorrhea and MRSA.

In vivo CRISPR screens identify genes that improve persistence and function of CAR-T cells in a model of cancer

Large analysis of genes and proteins in lung adenocarcinoma points to possible new diagnostic and treatment approaches, and also reveals signatures of chemical exposures in patients who have never smoked.

Tamoxifen encourages uterine cell growth in mice without causing mutations; findings could change how some breast cancers are treated in the future

The BrightSeq clinical research and testing initiative aimed at bringing liquid biopsy and genomic technologies into routine clinical care.

Test of circulating tumor cells offers less invasive option for multiple myeloma surveillance, staging, and biological study compared to bone marrow biopsies

Findings suggest that previously-approved precision medicines may benefit children with certain childhood brain tumors.

Developed in collaboration with ӳ����ý Clinical Labs and Mass General Brigham Laboratory for Molecular Medicine, the test provides a comprehensive view of a patient’s inherited heart disease risk.

Researchers double the number of genetic factors associated with this common arrhythmia, highlighting biological pathways that could be targeted by new medicines.

Low-oxygen air prevented and even reversed symptoms in a mouse model of Parkinson’s disease.

Scientists discover possible way to harness immune cells in the brain to remove plaques associated with Alzheimer's.

Researchers studying brain cells from Huntington’s patients show that the mutation, which changes over decades, becomes toxic only later in life.

Making single-letter edits in stretches of repeated DNA stopped or reversed the genetic change that causes Huntington’s disease and Friedreich’s ataxia.

Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.

Scientists find combinations of known antibiotics and other molecules that, together, have greater bacteria-killing power.

AI-based approaches yield novel antibiotics that show promise against gonorrhea and MRSA.